Polycystic Ovary Syndrome: Comprehensive Overview and Diagnostic Criteria

August 2007 in “ The Lancet ”

Robert J. Norman, Didier Dewailly, Richard S. Legro, Theresa E. Hickey

From the encyclopedia

diabetes drug with anti-inflammatory, immunomodulatory, and insulin-sensitizing properties

An essential vasodilator with some anti-androgenic effects

Studysummary This article reviews the clinical features, diagnostic criteria, and possible genetic and environmental influences of polycystic ovary syndrome but provides no new research findings.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer

View this study on thelancet.com →

Discuss this study in the Community →

Research cited in this study

10 / 10 results

Criteria for Defining Polycystic Ovary Syndrome as a Predominantly Hyperandrogenic Syndrome: An Androgen Excess Society Guideline

research Criteria for Defining Polycystic Ovary Syndrome as a Predominantly Hyperandrogenic Syndrome: An Androgen Excess Society Guideline

1744 citations , August 2006 in “The Journal of Clinical Endocrinology and Metabolism”

This review discusses definitions of polycystic ovary syndrome and reports no new clinical results; the authors support using modified 1990 NIH criteria and acknowledge ongoing evolution as research advances.

research Metformin Treatment of Polycystic Ovary Syndrome Improves Health-Related Quality of Life, Emotional Distress, and Sexuality

105 citations , March 2006 in “Human reproduction”

This study found that metformin treatment improved health-related quality-of-life, emotional well-being, and sexual satisfaction among women with PCOS, correlated with weight loss and menstrual cycle normalization.

research Relative Prevalence of Different Androgen Excess Disorders in 950 Women Referred Because of Clinical Hyperandrogenism

352 citations , January 2006 in “The Journal of Clinical Endocrinology and Metabolism”

This study reported that classic anovulatory PCOS was the most common androgen excess disorder, followed by mild ovulatory PCOS and idiopathic hyperandrogenism, among patients evaluated for clinical hyperandrogenism.

Health-Related Quality of Life in Women with Polycystic Ovary Syndrome: A Comparison with the General Population Using the Polycystic Ovary Syndrome Questionnaire and the Short Form-36

research Health-Related Quality of Life in Women with Polycystic Ovary Syndrome: A Comparison with the General Population Using the Polycystic Ovary Syndrome Questionnaire and the Short Form-36

167 citations , January 2006 in “Gynecological Endocrinology”

This study found that women with polycystic ovary syndrome reported a poorer health-related quality of life compared to women in the general population and patients with other medical conditions.

research Health Care-Related Economic Burden of Polycystic Ovary Syndrome During the Reproductive Life Span

414 citations , August 2005 in “The Journal of Clinical Endocrinology and Metabolism”

This study estimates the total cost of evaluating and treating polycystic ovary syndrome in reproductive-aged women in the United States to be $4.36 billion, suggesting more liberal screening could be beneficial.

research A Randomized, Placebo-Controlled Trial of 5% and 2% Topical Minoxidil Solutions in the Treatment of Female Pattern Hair Loss

219 citations , March 2004 in “Journal of The American Academy of Dermatology”

In this 48-week trial, 5% topical minoxidil was more effective than both 2% minoxidil and placebo in promoting hair growth in women with female pattern hair loss, with notable improvements in nonvellus hair count and hair growth assessments.

research Revised 2003 Consensus on Diagnostic Criteria and Long-Term Health Risks Related to Polycystic Ovary Syndrome

4809 citations , January 2004 in “Fertility and Sterility”

This review discusses polycystic ovary syndrome, emphasizing its broad range of manifestations and associations with risks like type 2 diabetes and cardiovascular events, but reports no new clinical results.

research Revised 2003 Consensus on Diagnostic Criteria and Long-Term Health Risks Related to Polycystic Ovary Syndrome (PCOS)

4025 citations , December 2003 in “Human Reproduction”

This review discusses the evolution of diagnostic criteria for polycystic ovary syndrome and emphasizes its association with various metabolic and cardiovascular risks, but it provides no new research findings.

research Association Between the D19S884 Marker at the Insulin Receptor Gene Locus and Polycystic Ovary Syndrome

48 citations , January 2003 in “Fertility and Sterility”

In this study, researchers found no significant association between the D19S884 marker near the insulin receptor gene and polycystic ovary syndrome in women from Spain and Italy.

research Androgenetic Alopecia: Pathogenesis and Potential for Therapy

174 citations , November 2002 in “Expert Reviews in Molecular Medicine”

This review discusses the genetic factors contributing to androgenetic alopecia and highlights the potential for developing more effective therapies based on recent discoveries, but reports no new clinical results.